Strategic Partnerships Gero's recent partnership with Pfizer and other pharmaceutical companies signifies a focus on collaborative research and development initiatives. Leveraging these partnerships could open doors for co-branded solutions and expanded market reach.
Funding Success With recent funding rounds totaling $6 million, Gero demonstrates financial stability and investor confidence. Targeting investors interested in biotechnology and AI-driven drug discovery can lead to potential funding opportunities or strategic alliances.
Biotech Innovation Gero's use of AI for drug discovery in age-related diseases sets them apart in the biotechnology industry. Positioning Gero as an innovative partner for pharmaceutical companies seeking breakthrough solutions in age-related health challenges can drive sales prospects.
Research Collaborations The collaborations with institutions like Roswell Park and the focus on research publications indicate Gero's commitment to advancing scientific understanding. Engaging with academia and research-focused organizations could yield sales opportunities through joint projects or knowledge-sharing initiatives.
Industry Expansion As a preclinical stage biotechnology company, Gero's expansion into AI-driven drug discovery presents growth potential. Exploring new markets beyond age-related diseases, such as chronic illnesses, can diversify sales pipelines and create avenues for product development partnerships.
51
$10M$50M
66$10M$50M
881$100M$1B
275$50M$100M
81$10MGero uses 8 technology products and services including Google Analytics, Yandex.Metrika, Cloudflare CDN, and more. Explore Gero's tech stack below.
| Gero Email Formats | Percentage |
| First.Last@gero.ai | 42% |
| FL@gero.ai | 8% |
| First.Last@gero.ai | 42% |
| FL@gero.ai | 8% |
Biotechnology ResearchCalifornia, United States51-200 Employees
We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once. You can find our publications here: https://gero.ai/publications
Company Overview
Media & News
Funding & FinancialsGero has raised a total of $6M of funding over 3 rounds. Their latest funding round was raised on Oct 18, 2023 in the amount of $6M.
Gero's revenue is in the range of $10M
Funding & FinancialsGero has raised a total of $6M of funding over 3 rounds. Their latest funding round was raised on Oct 18, 2023 in the amount of $6M.
Gero's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com